Live feed07:00:00·13dPRReleasevia QuantisnowKymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS CongressesByQuantisnow·Wall Street's wire, on your screen.KYMR· Kymera Therapeutics Inc.Health Care
